Regulation by C5a of neutrophil activation during sepsis

Immunity

Volumn 19, Issue 2, 2003, Pages 193-202

  Riedemann, Niels C ^a   Guo, Ren Feng ^a   Bernacki, Kurt D ^a   Reuben, Jayne S ^a   Laudes, Ines J ^a   Neff, Thomas A ^a   Gao, Hongwei ^a   Speyer, Cecilia ^a   Sarma, Vidya J ^a   Zetoune, Firas S ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CECUM; CYTOKINE PRODUCTION; GENETIC TRANSCRIPTION; IMMUNITY; LEUKOCYTE ACTIVATION; LIGATION; LUNG ALVEOLUS MACROPHAGE; NEUTROPHIL; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SEPSIS;

EID: 0041931068     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(03)00206-1     Document Type: Article

References (31)

1. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
2. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., Schmal H., Friedl H.P., Ward P.A. Protective effects of C5a blockade in sepsis. Nat. Med. 5:1999;788-792.
3. de Boer J.P., Creasey A.A., Chang A., Roem D., Eerenberg A.J., Hack C.E., Taylor F.B. Jr. Activation of the complement system in baboons challenged with live Escherichia coli. correlation with mortality and evidence for a biphasic activation pattern Infect. Immun. 61:1993;4293-4301.
4. Dubravec D.B., Spriggs D.R., Mannick J.A., Rodrick M.L. Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA. 87:1990;6758-6761.
5. Eskandari M.K., Bolgos G., Miller C., Nguyen D.T., DeForge L.E., Remick D.G. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:1992;2724-2730.
6. Goldstein I.M., Weissmann G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 113:1974;1583-1588.
7. Guo R.F., Huber-Lang M., Wang X., Sarma V., Padgaonkar V.A., Craig R.A., Riedemann N.C., McClintock S.D., Hlaing T., Shi M.M.et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J. Clin. Invest. 106:2000;1271-1280.
8. Huber-Lang M., Sarma V.J., Lu K.T., McGuire S.R., Padgaonkar V.A., Guo R.F., Younkin E.M., Kunkel R.G., Ding J., Erickson R.et al. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166:2001;1193-1199. a.
9. Huber-Lang M.S., Sarma J.V., McGuire S.R., Lu K.T., Guo R.F., Padgaonkar V.A., Younkin E.M., Laudes I.J., Riedemann N.C., Younger J.G.et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J. 15:2001;568-570. b.
10. Huber-Lang M.S., Younkin E.M., Sarma J.V., McGuire S.R., Lu K.T., Guo R.F., Padgaonkar V.A., Curnutte J.T., Erickson R., Ward P.A. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169:2002;3223-3231.
11. Jin F.Y., Nathan C., Radzioch D., Ding A. Secretory leukocyte protease inhibitor. a macrophage product induced by and antagonistic to bacterial lipopolysaccharide Cell. 88:1997;417-426.
12. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2:2002;725-734.
13. Matsumoto T., Yoshida S., Shiga Y., Kikuchi M., Sata T., Shigematsu A. Contribution of neutrophils to lipopolysaccharide-induced tumor necrosis factor production and mortality in a carrageenan-pretreated mouse model. FEMS Immunol. Med. Microbiol. 17:1997;171-178.
14. McDonald P.P., Bald A., Cassatella M.A. Activation of the NF-kappaB pathway by inflammatory stimuli in human neutrophils. Blood. 89:1997;3421-3433.
15. McDonald P.P., Bovolenta C., Cassatella M.A. Activation of distinct transcription factors in neutrophils by bacterial LPS, interferon-gamma, and GM-CSF and the necessity to overcome the action of endogenous proteases. Biochemistry. 37:1998;13165-13173.
16. Nakae H., Endo S., Inada K., Takakuwa T., Kasai T., Yoshida M. Serum complement levels and severity of sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84:1994;189-195.
17. Newcomb D., Bolgos G., Green L., Remick D.G. Antibiotic treatment influences outcome in murine sepsis. mediators of increased morbidity Shock. 10:1998;110-117.
18. Nick J.A., Avdi N.J., Young S.K., Lehman L.A., McDonald P.P., Frasch S.C., Billstrom M.A., Henson P.M., Johnson G.L., Worthen G.S. Selective activation and functional significance of p38alpha mitogen- activated protein kinase in lipopolysaccharide-stimulated neutrophils. J. Clin. Invest. 103:1999;851-858.
19. Pan Z.K. Anaphylatoxins C5a and C3a induce nuclear factor kappaB activation in human peripheral blood monocytes. Biochim. Biophys. Acta. 1443:1998;90-98.
20. Riedemann, N.C., Guo, R.-F., Laudes, I.J., Keller, K., Sarma, V.J., Padgaonkar, V., Zetoune, F.S., and Ward, P.A. (2002a). C5a receptor and thymocyte apoptosis in sepsis. Faseb J 16, 887-888. Published online April 23, 2002. 10.1096/fj.02-0033fje.
21. Riedemann N.C., Guo R.F., Neff T.A., Laudes I.J., Keller K.A., Sarma J.V., Markiewski M.M., Mastellos D., Strey C.W., Pierson C.L.et al. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110:2002;101-108. b.
22. Riedemann N.C., Guo R.F., Sarma V.J., Laudes I.J., Huber-Lang M., Warner R.L., Albrecht E.A., Speyer C.L., Ward P.A. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 168:2002;1919-1925. c.
23. Sacks T., Moldow C.F., Craddock P.R., Bowers T.K., Jacob H.S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J. Clin. Invest. 61:1978;1161-1167.
24. Schumacher W.A., Fantone J.C., Kunkel S.E., Webb R.C., Lucchesi B.R. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions. 34:1991;345-349.
25. Shin H.S., Snyderman R., Friedman E., Mellors A., Mayer M.M. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science. 162:1968;361-363.
26. Smedegard G., Cui L.X., Hugli T.E. Endotoxin-induced shock in the rat. A role for C. 5a.(Am. J. Pathol. 135):1989;489-497.
27. Solomkin J.S., Jenkins M.K., Nelson R.D., Chenoweth D., Simmons R.L. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery. 90:1981;319-327.
28. Taggart C.C., Greene C.M., McElvaney N.G., O'Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced Ikappa Balpha degradation without affecting phosphorylation or ubiquitination. J. Biol. Chem. 277:2002;33648-33653.
29. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., Hariri R.J., Fahey T.J. 3rd, Zentella A., Albert J.D.et al. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470-474.
30. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
31. Wilkinson B.J., Sisson S.P., Kim Y., Peterson P.K. Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M. implications for the mechanism of resistance to phagocytosis Infect. Immun. 26:1979;1159-1163.